Table of Contents Table of Contents
Previous Page  678 / 812 Next Page
Information
Show Menu
Previous Page 678 / 812 Next Page
Page Background

S674

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

EV1015

The psychotropic effects of

anti-epileptic drugs: A review

A. Guerra

, D. Ferreira , C. Pereira , M. Carvalho

Hospital de Santa Maria – Centro Hospitalar Lisboa Norte, Psychiatry

and Mental Health Department, Lisbon, Portugal

Corresponding author.

Anti-epileptic drugs (AEDs) are psychotropic agents that are

widely used for the treatment of a variety of neurological condi-

tions and psychiatric disorders. Although the association between

psychopathology and AED therapy has long been recognized, a sys-

tematic evaluation of its effects on mood and behaviour has taken

place only more recently. A literature review, based on a PubMed

research, takes stock of the studies that have investigated this sub-

ject in the latest years. Depending on the drug, its efficacy and the

individual’s biological and psychological predisposition, all AEDs

may lead to positive or negative psychotropic effects. The exact fre-

quency of psychiatric adverse events related to AEDs is difficult to

estimate, but behavioural problems seem to be the most common,

followed by depressive disorders. Psychosis is a relatively rare,

although severe, complication. The AEDs’ potential psychotropic

effects will be addressed in detail, with special focus on their mood,

behavioural and cognitive profile, aswell as themechanisms under-

lying these events. When recognized at an early stage, psychiatric

complications are in most cases mild and reversible. Risk factors

are not a strict indication for any particular drug, but side effect

profiles, including negative and positive psychotropic effects, must

be considered in the choice of the optimal drug for the individ-

ual patient. The studies regarding this subject are limited as they

are designed to test anti-epileptic efficacy and psychiatric adverse

events are not systematically reported. This subject also warrants

further research since many relevant aspects concerning patholog-

ical mechanisms, frequency, psychopathology and prognosis are

not well understood.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2000

EV1016

Antipsychotic medications and

cardiometabolic risk – A review of

current literature

S. Gunturu

1 ,

, K. Shah

2

, P. Korenis

2

, S. Lawler

3

, M. Kucheria

2

1

New York, USA

2

Bronx Lebanon Hospital Centre, Psychiatry, New York, USA

3

American University of Caribbean, Psychiatry, Sint Maarten,

Trinidad and Tobago

Corresponding author.

In the USA, 68% of adults and 31% of children are overweight or

obese. Obesity doubles mortality rates and has significant associ-

ated medical costs with an average obese person spending $1500

or more per year. In addition, 10% of all adults and 23% of adults

over 60 years have type 2 diabetes, with an average person spend-

ing $2257 or more per year. In 2009, 1 out of every 10 healthcare

dollars was spent on type 2 diabetes, totalling $174 billion. Peo-

ple with serious and persistent mental illness die on average 25

years earlier than the general population. Cardiovascular disease

is the primary cause of death in persons with mental illness and

accounts for 60% of the increased mortality. Furthermore, 46.24%

of individuals with cardiometabolic risk factors who are also on

antipsychotic medications take high- to moderate-risk antipsy-

chotics. The cluster of cardiometabolic syndrome includes: type

2 diabetes, hypertension, dyslipidemia, obesity and pre-existing

cardiovascular disease. There are, however, modifiable risk fac-

tors including smoking cessation, diet change, physical activity,

medical care and choice of antipsychotic medication (on which

the physician has direct control). More information is therefore

needed on various antipsychotic medications and their associ-

ated cardiometabolic risk factors in order to educate physicians.

In this review article, we examined 10 articles on antipsychotic

medications, and their effect on the 5 domains, including type 2

diabetes, hypertension, dyslipidemia, obesity and pre-existing car-

diovascular disease. Overall, there was a clear trend, which found a

significant difference in the associated risk factors amongst various

antipsychotic medications.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2001

EV1017

Clinical predictors of clozapine

response

K. Hajji

1 ,

, I. Laajmi

2

, I. Marrag

2

, S. Fathallah

2

, M. Nasr

2

1

Boulogne Billancourt, France

2

Hospital of Mahdia of Psychiatry Mahdia, Mahdia, Tunisia

Corresponding author.

Introduction

Schizophrenia is a chronic, severe, and disabling

mental disorder. An evaluation of clinical predictors to clozapine

was described.

Object

Identify clinical predicting factors to clozapine.

Methods

This is a cross-sectional study including patients diag-

nosed with schizophrenia or schizoaffective disorder according to

the DSM 5 criteria and treated with clozapine.

Results

Of the 33 patients, 78.8% were males and 69.7% of them

were single. The mean age was 36 years old. The mean age at the

onset of the disorder was 24 years old. The mean number of hospi-

talizations was 6. The beginning of themental disorder was acute in

21.2% of the cases. The mean duration of the disease course before

starting clozapine treatment was 11 years. The mean duration of

treatment was 19 months. The diagnosis according to DSM 5 crite-

ria was schizophrenia in 87.9 and schizoaffective disorder in 12.1%

of cases. The outcome was assessed by PANSS and BPRS scales with

a symptomatic remission in 63.63% of cases. The analytical study

revealed a significant correlation between favorable evolution and

the latest onset of the disorder (

P

= 0.04), the number of previous

hospitalizations (

P

= 0.009), disorder’s duration (

P

= 0.032), male sex

(

P

= 0.0004) and secondary resistance (

P

< 10

3).

Conclusion

The evaluation of clinical factors is important in our

practice in order to improve the response to clozapine. Otherwise,

adherence to treatment and quality of insight are determining fac-

tors of the treatment response.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2002

EV1018

Paliperidone palmitate versus other

antipsychotics

P. Hervías Higueras

1 ,

, L. Maroto Martín

1

, S. Raffo Moncloa

1

,

M. Leonor del Pozo

2

1

Hospital Dr. R. Lafora, Psiquiatría, Madrid, Spain

2

Hospital Dr. R. Lafora, UHB Psiquiatría, Madrid, Spain

Corresponding author.

The aim of the study was to describe the psychopharmacological

treatments received by inpatients diagnosed with spectrum disor-

ders schizophrenia and other psychotic disorders in Dr. Rodriguez

Lafora Hospital. It is an observational, descriptive and retrospec-

tive study. We collected information about patients aged 18 to

64 who were hospitalized during the month of January of 2015

in the acute psychiatric hospitalization by Selene software. We

reviewed treatments and number of psychiatric re-hospitalization

six months later and we analyzed the results by SPSS software.